12,372 trials
Homozygous Familial Hypercholesterolemia
Primary: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) — 8.6; -26.9 Percentage of change — p=<0.0001
Pediatric Growth Hormone Deficiency
Primary: Annual Height Velocity in Main Study Phase — 10.10; 9.78 cm/year
Type 2 Diabetes Mellitus · Chronic Kidney Disease Stage 4
Primary: Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo — -0.11; -0.40 percentage of HbA1c — p=0.0962
Supra-ventricular Tachycardia
Primary: The Number of Patients With First Dose Successful Termination of the Supraventricular Tachycardia to a Sinus Rhythm of Less Than 140 With the AHA Versus a Simplified…
Leukemia, Myeloid, Acute
Primary: Intensive Study: Overall Survival (OS) — 17.3; 20.4 months — p=0.6579
Osteoarthritis · Cancer Pain · Recurrent Low Back Pain
Primary: Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age — 38.7; 38.7 cm
Plaque Psoriasis
Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement — 3.4; 79.9; 86.4…
Type 2 Diabetes Mellitus · Chronic Kidney Disease Stage 3
Primary: Change From Baseline in HbA1c at Week 26 — -0.22; -0.32; -0.46 percentage of HbA1c — p=0.2095
Herpes Labialis
Primary: Number of Participants Reported Adverse Events (AEs), Serious Adverse Events (SAEs) — 6; 6; 0; 0 Participants
Peri-Implantitis
Primary: Absolute Change in Mean Probing Pocket Depth for Selected Target Implants — -1.69; -1.51 mm — p=0.1159
Covid19 · SARS (Severe Acute Respiratory Syndrome)
Primary: 14 Day Recovery Rate — 258; 117 Participants
Non-small Cell Lung Cancer
Primary: Overall Survival — 11.79; 8.25 Months
Respiratory Tract Infections
Primary: Percentage of Subjects With Clinically Symptomatic Respiratory Illness — 125; 134 Participants
Rosacea
Primary: Percentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Treatment Success Was Defined as Having a Clinician…
Advanced Cancer
Primary: Disease-free Survival (DFS) — 22.41; 11.04 Months — p=0.0003